Clinical Trials Directory

Trials / Completed

CompletedNCT00529711

The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Innogene Kalbiotech Pte. Ltd · Industry
Sex
All
Age
45 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Previous clinical trials with 11.2% Hypertonic Ringer's Lactate in post-operative CABG subjects have shown an increase in several cardiac performance parameters, with lesser volume of resuscitation fluid required to reach circulation volume, as compared to Sodium Chloride.It also does not cause hyperchloremic acidosis, which is of value in treating shock patients. The primary objectives of this prospective, randomized, open-label trial are to evaluate the clinical efficacy of hypertonic lactate in comparison to Ringer's lactate to maintain hemodynamic stability in intra- and post-CABG subjects in relation to hemodynamic status and body fluid balance, as well as to assess its safety in terms of lab parameters and occurrence of adverse events.The secondary objectives are to evaluate comparative clinical efficacy of the two fluids in relation to reduction in concomitant drug utilization, duration of ventilator usage, length of stay in ICU as well as total duration of hospitalization and neurocognitive status upto a period of 1 year post-CABG.

Detailed description

Details provided in summary.

Conditions

Interventions

TypeNameDescription
DRUGHypertonic lactateSolution given parenterally as follows: Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
DRUGRinger's lactateSolution given parenterally as follows: Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.

Timeline

Start date
2005-07-01
Completion
2006-07-01
First posted
2007-09-14
Last updated
2007-09-14

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT00529711. Inclusion in this directory is not an endorsement.